Gilead Sciences, Inc. has recently announced its definitive agreement to acquire Arcellx for $115 per share in cash at closing and one contingent value right of $5 per share, totaling an implied equity value of $7.8 billion. This acquisition provides Gilead with full control of anito-cel, accelerating its development and commercialization while eliminating profit-share, milestones, and royalties. The transaction is expected to be accretive to earnings per share in 2028 and thereafter upon FDA approval of anito-cel.
Anito-cel, a potentially transformative treatment for patients with multiple myeloma, has shown deep and durable responses with a manageable safety profile in clinical studies. The Biologics License Application (BLA) for anito-cel as a fourth-line treatment for patients with relapsed or refractory multiple myeloma has been accepted by the U.S. Food and Drug Administration with an anticipated Prescription Drug User Fee Act (PDUFA) action date of December 23, 2026.
The terms of the acquisition were approved by both Gilead and Arcellx boards of directors and are anticipated to close during the second quarter of 2026, subject to customary closing conditions. Gilead currently owns approximately 11.5 percent of Arcellx’s outstanding common stock.
Upon completion of the acquisition, Gilead aims to maximize the long-term potential of anito-cel, which could become a foundational treatment for multiple myeloma over time, including earlier lines of therapy. In addition to anito-cel, Arcellx’s D-domain CAR technology platform has potential applications in next-generation CAR T-cell and bispecific therapies.
This acquisition not only reflects Gilead’s conviction in the potential of anito-cel but also its intention to move swiftly to benefit patients with multiple myeloma. Gilead's commitment to advancing innovative medicines for life-threatening diseases, including cancer, is further strengthened through this acquisition. As a result of these announcements, the company's shares have moved 3.01% on the market, and are now trading at a price of $124.91. For more information, read the company's full 8-K submission here.
